TC BioPharm Limited Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Share-based payments (Tables)

12 Months Ended

Dec. 31, 2021

	Number of share options		Weighted average exercise price £

Outstanding at January 1, 2021		5,329,230		0.46
Granted during the period		-		-
Exercised during the period		-		-
Forfeited during the period		-		-
Outstanding at December 31, 2021		5,329,230		0.46

Exercisable at December 31, 2021		5,329,230		0.46
Not exercisable at December 31, 2021		-		-

No options were granted or exercised in the period to December 31 2021.

	Number of share options			Weighted average exercise price
				£

Outstanding at January 1, 2020		4,966,740			0.42
Granted during the period		465,490			1.08
Exercised during the period		-			-
Forfeited during the period		(103,000	)		1.31
Outstanding at December 31, 2020		5,329,230			0.46

Exercisable at December 31, 2020		5,329,230			0.46
Not exercisable at December 31, 2020		-			-

TC BIOPHARM (HOLDINGS) PLC

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

19.

Share-based payments (continued)

	Number of share options			Weighted average exercise price
				£

Outstanding at January 1, 2019		4,221,050			0.10
Granted during the period		823,190			2.07
Exercised during the period		-			-
Forfeited during the period		(77,500	)		0.60
Outstanding at December 31, 2019		4,966,740			0.42

Exercisable at December 31, 2019		4,492,740			0.32
Not exercisable at December 31, 2019		474,000			1.34

		2020			2019
The model inputs were as follows:
		2020			2019
Weighted average share price		£	2.16			3.85
Expected volatility			75	%		70	%
Risk free interest rate			0.01	%		0.50	%
Expected option life			1 year			2 years
Dividend yield	%		0.0	%		0.0	%

The model inputs were as follows:

	2020
Weighted average share price		4.16
Expected volatility		70	%
Risk free interest rate		0.30	%
Expected option life		1.33 years
Dividend yield		0.0	%